Glenmark Pharmaceuticals
GLENMARK · NSE · Pharma · India
Financials at a glance
Source: Yahoo FinanceAnnual
Quarterly · last 5
Revenue (FY2026)
₹16,983 Cr
Net margin
8.0%
Revenue CAGR (3y)
+9.3%
Profit CAGR (3y)
+66.1%
Net profit (FY2026)
₹1,362 Cr
Ask MarketChacha about GLENMARK
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Jul 29, 2026
Glenmark's US subsidiary launched Sugammadex Injection (generic) single-dose vials in the US market, a product with ~$1.6B in annual sales, per the July 28 BSE press release.
Daily moves with the verified reason behind them. Education only — not investment advice.
Financials
Yearly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| FY2026 | ₹16,983 Cr | ₹1,362 Cr | 8.0% |
| FY2025 | ₹13,322 Cr | ₹1,047 Cr | 7.9% |
| FY2024 | ₹11,813 Cr | ₹-1,502 Cr | -12.7% |
| FY2023 | ₹12,990 Cr | ₹297 Cr | 2.3% |
Quarterly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| Q1 FY27 | ₹4,018 Cr | ₹483 Cr | 12.0% |
| Q4 FY26 | ₹3,771 Cr | ₹301 Cr | 8.0% |
| Q3 FY26 | ₹3,901 Cr | ₹403 Cr | 10.3% |
| Q2 FY26 | ₹6,047 Cr | ₹610 Cr | 10.1% |
| Q1 FY26 | ₹3,264 Cr | ₹47 Cr | 1.4% |
Figures as reported, in ₹ (crore). Source: Yahoo Finance.
Filings & announcements
2026
Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....
BSE8/21/2026Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray
BSE8/20/2026Letter to Shareholders whose email address are not registered providing the web link of Annual Report
BSE8/13/2026Business Responsibility and Sustainability Reporting (BRSR)
Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-26
BSE8/13/2026Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.
BSE8/13/2026Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
BSE8/11/2026Investor Presentation - Q1 FY 26-27
BSE7/31/2026Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
BSE7/28/2026
In the news
- Glenmark stock gains on strong Q1 profits and investor meetingsAD HOC NEWS · 9/4/2026
- Buy, Sell Or Hold: Vishal Mega Mart, HDFC Bank, Shriram Finance, Ather Energy And Glenmark Pharma — Ask ProfitNDTV Profit · 8/31/2026
- GLENMARK Share Price | Glenmark Pharmaceuticals Ltd. Stock Analysis & RecommendationMarketsMojo · 8/31/2026
- Stocks to buy: What's the outlook for Nifty for August 31-September 4 week? Check list of top stock recomThe Times of India · 8/31/2026
- Glenmark Pharmaceuticals Share Price falls 2.01% todayunivest.in · 8/31/2026
- Stocks To Buy Today: Coforge, Timex To Glenmark Pharma — Five Stock Picks By Motilal Oswal's Chandan TapariaNDTV Profit · 8/31/2026
- Top stocks in news: HDFC Bank, RIL, Augmont, M&M, LEAP, Auro Pharma, Cipla, NBCC, Clean Max, OlaBusiness Today · 8/31/2026
- Dividend Stocks To Watch: Coal India, NTP, ONGC, Shipping Corp, Gail, Glenmark Pharma, Mastek And 82 Others; Check Full ListNDTV Profit · 8/30/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.